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Resumo 
 
Objetivo: Este estudo tem como objetivo: i) revisar a literatura e sintetizar as 
informações sobre a relação entre pacientes oncológicos frágeis e readmissão 
hospitalar após a cirurgia e ii) comparar a prevalência e concordância de 
diferentes instrumentos de fragilidade em pacientes oncológicos eleitos para 
tratamento cirúrgico. 
Métodos: O primeiro objetivo foi alcançado através da realização de uma revisão 
sistemática e metanálise. O segundo objetivo foi alcançado através da realização 
de um estudo observacional transversal com pacientes oncológicos aguardando 
cirurgia, onde foram testados 5 instrumentos amplamente utilizados para avaliar 
a fragilidade (Fragilidade Fenotípica, VES-13, velocidade da marcha, 8 foot up-
and-go e força de preensão manual). 
Resultados: Com a metanálise, observamos uma relação positiva entre a 
presença de fragilidade e o risco de readmissão hospitalar após a cirurgia (RR = 
1,58; IC95% 1,07-2,33; P = 0,02), embora com heterogeneidade significativa (p 
= 0,05, e I2 = 54%). Com o estudo transversal, nossos dados sugerem que a 
prevalência de fragilidade variou amplamente (8,2 a 37,3%), dependendo do 
instrumento de avaliação e sua concordância foi limitada. 
Conclusão: A fragilidade é uma medida valiosa para a avaliação pré-operatória 
de pacientes submetidos à cirurgia, principalmente para predizer aqueles em 
risco de readmissão hospitalar. No entanto, o instrumento para avaliar a 
fragilidade deve ser selecionado com cuidado, pois diferentes instrumentos 
geralmente têm uma concordância ruim e, portanto, podem levar a uma previsão 
de risco incorreta. 
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Abstract 
 
Objective: This study aims to: i) review the literature and summarize the 
information regarding the relation between frail oncologic patients and hospital 
readmission after surgery and ii) compare the prevalence and agreement of 
different frailty tools in oncologic patients elected for surgical treatment. 
Methods: The first aim was accomplished by performing a systematic review and 
meta-analysis. The second aim was accomplished by perform an observational 
cross-sectional study with cancer patients waiting for surgery, where tested 5 
instruments widely used to assess frailty (Phenotypic Frailty, VES-13, gait speed, 
8 foot up-and-go and hand grip strength).  
Results: with the meta-analysis, we observed a positive relation between the 
presence of frailty and risk of hospital readmission after surgery (RR=1.58, 95% 
CI 1.07-2.33; P = 0.02) though with significant heterogeneity (p=0.05, and I2 = 
54%). With the cross-sectional study, our data suggest that prevalence of frailty 
varied widely (8.2 to 37.3%) depending on the assessment tool and their 
agreement was limited. 
Conclusion: Frailty is a valuable measure for the preoperative assessment of 
patients submitted to surgery, particularly to predict those at risk of hospital 
readmission. However, the instrument to assess frailty should be carefully 
selected, as different instruments often have poor agreement and thus, might 
lead to wrong risk prediction. 
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Abbreviations and symbols  
 
5m= 5m Gait Speed 
BMI= Body Mass Index 
CI= confidence interval 
Fried= Phenotypic Frailty test  
I2= Heterogeneity  
K=kappa coefficient  
r = Pearson correlation 
RR= Risk ratio 
Ves-13= The Vulnerability Elders Survey 
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Introduction 
 
Frailty can be defined as a state of vulnerability that leads to adverse 
health outcomes, being a multifaceted state of lowered physiological reserve, 
resulting in an increased vulnerability and decreased resistance and adaptive 
capacity [1]. As life expectancy grows, there is an exponential growth of ill and 
frail people in the population, consequently bringing costs to the society and the 
individual [2]. The concept of frailty has been studied and recognized as a very 
important determinant of health-related outcomes, especially in oncology, were 
frail patients have poor tolerance to anti-cancer treatments, high risk of 
complications to anti-cancer treatments and high risk of readmission and mortality 
[1, 3]. There are over 70 interventions and tools to measure frailty, though not all 
have been validated, differing from individual assessment tools to multi domain 
interventions [1]. This variety is major obstacle to clinicians, as it is difficult to 
choose one. Indeed, there is no standard instrument to assess frailty and all have 
its own advantages and disadvantages that need to be considered case-by-case 
according to the purpose and context of its use. In addition, it has been 
recognized that frailty prevalence varies within the same population depending 
on the instrument that was used. Thus, it is of uppermost importance to also 
assess the agreement between different instruments to help in the decision of 
which tool matches the needs of a clinical or researcher. For instance, if a more 
comprehensive (and thus time consuming) instrument has a good predictive 
value for a certain outcome (e.g. postoperative complications) and if a simple test 
(e.g. gait speed or handgrip strength) presents a good agreement, than we could 
opt by the faster on when time is a constrain [4]. By defining a gold standard frailty 
assessment, health professionals may predict adverse outcomes and define 
which patients may receive pre-habilitation care, to rise patient´s ability to go 
through the stress of surgery and decrease the occurrence of postoperative 
complications, shorten hospital stay, reduce unplanned readmission thus, reduce 
the burden of surgery [5]. In order to give some insights about some of these 
concerns, this study aims: 1) to review the literature and summarize the 
information regarding the relation between frail oncologic patients and hospital 
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readmission after surgery. To accomplish this, a systematic review and meta-
analysis was done and this will be presented in the first part of our work; 2) to 
compare the prevalence of frailty according to different instruments and test their 
agreement. To accomplish this, we will perform an observational cross-sectional 
study with cancer patients waiting for surgery and will test them for frailty using 5 
instruments widely used to assess frailty (Phenotypic Frailty, VES-13, gait speed, 
8 foot up-and-go and hand grip strength). This will be presented on the last part 
of this work. 
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Study 1: Frailty and the Risk of Hospital Readmission After 
Cancer Surgery: Systematic Review and Meta-Analysis 
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ABSTRACT 
 
Introduction: Surgery is often the only option for cancer treatment and cure, the 
number of patients requiring this type of surgery is expected to increase over the 
next few years. However, surgery may cause adverse outcomes, such morbidity 
and mortality, especially in frail patients. An unplanned readmission is common 
outcome, bringing risks and expenses, though can be prevented. Aim: This study 
aimed to identify the risk of post-surgery readmission for frail cancer patients 
through a meta-analysis and systematic review. 
Methods: This review was designed according to the Preferred Reporting Items 
for Systematic Reviews and Meta-Analysis (PRISMA). MEDLINE and LILACS 
electronic databases were searched between September 2018 and April 2019. 
In addition, the reference list of other publications was checked for any 
unidentified study. Newcastle – Ottawa Quality Assessment Scale (NOS) was 
utilized to assess the quality of studies and Data synthesis was performed 
according to recommendations in the Cochrane Handbook for Systematic 
Reviews of Interventions, using Review Manager 5.3 (software Cochrane 
Collaboration).  
Results: Nine observational studies were included in the meta-analysis, being 
22.3% of the total of patients frail that underwent surgery. An association was 
found of the higher risk of post-surgery readmission for frail patients, a positive 
association for frail patients and readmission was also found when analyzing 
colorectal cancer individually and a longer follow-up after surgery.  
Conclusion:  Patient readmission is an adverse outcome when it comes to 
surgery cancer patients, having frail patients a higher risk of readmission. Further 
studies need to be done to determine the reasons for patient readmission. 
 
 
KEYWORDS: READMISSION, FRAIL, SURGERY, CANCER, ONCOLOGY
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INTRODUCTION 
Demographic projections for Europe in 2030 indicate that 25% of the 
population will be 65 or over, being cancer the first cause of mortality [6]. Because 
surgery is the only curative option for solid cancers, particularly in early stage 
disease, it is estimated that the number of cancer patients requiring surgical 
treatment will increase. However, surgery is not free of adverse events such as 
risk for morbidity and mortality, particularly in the most vulnerable patients [7]. 
Unplanned hospital readmissions also are a common, expensive and often 
preventable postoperative adverse event for patients submitted to surgical 
treatment [8]. Despite the efforts on identifying those patients at highest risk of 
readmission, current options fail to accurately predict which patients will not 
successfully transition back into their normal lives [9-11]  
Frailty is defined as a clinical syndrome, which indicates an increased state 
of vulnerability, associated with a decline in physiologic reserve and function 
across multiple organ systems, resulting in adverse health outcomes, which could 
be increased or reverted by interventions [12]. Frail patients are at increased risk 
of chemotherapy intolerance, postoperative complications and mortality [13]. It 
has even been reported that frailty is a stronger predictor of postoperative 
outcomes compared with several classic surgical risk‐assessment tools [14-16]. 
Importantly, a higher number of positive frailty characteristics was associated with 
higher hospital readmission rate, suggesting that frailty might be useful to predict 
unplanned readmission and thus, its negative consequence  [3, 17, 18]. However, 
the evidence has not been systematized and thus, we conducted this meta-
analysis and systematic review with the intent to explore the association between 
frailty and the risk of post-surgery hospital readmission in cancer patients.  
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METHODS  
This review was designed according to the Preferred Reporting Items for 
Systematic Reviews and Meta-Analysis (PRISMA) statement [19]. 
Eligibility criteria  
We included studies that recruited adult patients aged 18 or older, of both 
sexes and any ethnicity, diagnosed with cancer and scheduled to surgery for 
tumor resection with and without neoadjuvant therapy. In addition, studies had to 
stratify and compare participants by frailty status, assessed before any treatment, 
using one or more frailty instrument.  
The primary outcome for this review was frailty prevalence and post-
operative readmission to the hospital. There was no minimum length of follow-up 
for the studies that were eligible for inclusion in the review, but they had to report 
the timing and duration of the readmission.  
Only published observational (retrospective and prospective) and 
experimental (non-randomized and randomized clinical trials) studies, reporting 
crude or sufficient raw data to allow calculation of the association between frailty 
and post-operative re-admission to hospital, published in English in the last 10 
years were considered eligible for inclusion in the review. The following criteria 
were used to exclude papers from analysis: articles that did not specify the 
postoperative complications and the readmission period, review papers, 
conference abstract, studies in languages other than English, studies that did not 
characterize participants by frailty status and studies with more than ten years.   
Information sources  
We searched MEDLINE and LILACS electronic databases between 
September 2018 and April 2019. In addition, the reference list of other 
publications was checked for any unidentified study.  
Search 
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The electronic search was performed using the terms “Frail/Frailty AND 
cancer/oncologic/oncology AND postoperative AND readmission”.  
Study selection 
The title and abstract of the selected studies were screened by one 
reviewer (GE) to determine eligibility in terms of intervention, participants, and 
design. If in doubt about whether a study was relevant, the full article was 
checked. The full-text versions of all relevant studies were retrieved. If a full text 
version could not be retrieved, then the study was excluded due to the lack of a 
detailed methodology and the possibility of a high risk of bias.  
Data collection process 
After applying the inclusion/exclusion criteria, the following information 
was retrieved from the selected articles: author, year, study design and location, 
participant population (sample size, age, gender), the inclusion and exclusion 
criteria, type of cancer, stage of cancer, type of treatment, type of surgery 
(elective or emergency), methods used to assess frailty and its prevalence, and 
readmission rates. All the information was organized into tables.  
Data items 
Only numerical values reported by the studies (e.g. percentages, counts, 
means) were used to calculate frailty prevalence and risk of post-surgery 
readmission. 
We anticipated the use of different frailty instruments and different 
classifications of frailty (frail and non-frail; frail, pre-frail and robust; cumulative 
frailty). Thus, and in order to include the greatest number of articles in this review 
and/or to perform analysis by frailty status, we dichotomized (frail and non-frail) 
or trichotomized (frail, pre-frail and robust) frailty classification. Regarding 
dichotomization, “pre-frail” and “robust” patients were merged and considered 
“non-frail”; for studies using cumulative frailty (from 0 to 1), we considered “non-
frail” those with a frailty index <0.2 and “frail” those ≥0.2 [20]. For trichotomization, 
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we considered “robust”, “pre-frail” and “frail” those with a frailty index ≤0.10, 0.10 
to 0.21 and >0.21, respectively [21].  
Risk of bias  
We used the Newcastle – Ottawa Quality Assessment Scale (NOS) to 
assess the quality of studies [22] . It uses a rating system, with a maximum of 
nine stars rewarded to judge the best level quality, distributed by three multi-item 
domains: selection (4 possible stars), comparability (2 possible stars) and 
outcome (3 possible stars). At the end all the stars were summed, and the scoring 
was rated to Agency for Healthcare Research and Quality (AHRQ) standards 
(good, fair, and poor) as follows: Good quality if 3 or 4 stars in Selection domain 
AND 1 or 2 stars in Comparability domain AND 2 or 3 stars in Outcome domain; 
Fair quality if 2 stars in Selection domain AND 1 or 2 stars in Comparability 
domain AND 2 or 3 stars in Outcome domain; Poor quality if 0 or 1 star in 
Selection domain OR 0 stars in Comparability domain OR 0 or 1 stars in Outcome 
domain. The assessment of risk of bias was also used to inform for the sensitivity 
analysis, where only data retrieved from studies judged as “Good” quality were 
considered. 
Summary of measures 
Readmission was expressed as Risk Ratio (RR) with 95% confidence 
intervals (CI).  
Synthesis of results 
Data synthesis was performed according to recommendations in the 
Cochrane Handbook for Systematic Reviews of Interventions, using Review 
Manager 5.3 (software Cochrane Collaboration). We calculated pooled risk ratio 
(RR) and 95% confidence intervals (95% CI) using the Mantel – Haenszel 
method. The random-effects mode was used because we assume that the true 
effect size varies from one study to the next, and that the studies in our analysis 
12 
 
represent a random sample of effect sizes that could have been observed. Only 
unadjusted data was pooled. 
Assessment of heterogeneity 
Statistical heterogeneity was observed by visual inspection of forest plots, 
by using a standard Chi2 value with a significance cut off level of P < 0.10, and 
by the I2 statistic.  An I2 estimate greater than or equal to 50% with a significant 
value for Chi2, was interpreted as evidence of statistical heterogeneity [23]. 
Assessment of reporting biases 
Funnel plots were used to visually inspect for publication bias. 
Subgroup analysis 
Subgroup analysis was conducted, according to the following: frailty status 
(robust vs. pre-frail vs. frail), cancer type (gynecologic vs. digestive), time of 
readmission (<30 and > 30 days), sample size (>100 and <100), type of treatment 
and type of study (prospective and retrospective).  
Sensitivity analysis 
Sensitivity analysis was performed by omitting every single study and re-
calculating the RR. 
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RESULTS 
Study Selection 
A PRISMA diagram summarizing flow of studies through the review is 
presented (Figure 1). After the initial literature search, we identified 1073 articles 
and abstracts through database searching, and 16 additional articles from 
references of other reviews. After screening, only 74 articles remained to be 
assessed for eligibility and 48 papers were discarded because they were not 
related with the topic. After applying the inclusion and exclusion criteria on the 
remaining 26 articles, only 9 were eligible for qualitative and quantitative 
evaluation. Reasons for exclusion are listed in Table 1.  
 
Figure 1: PRISMA Flow Diagram. 
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Table 1: Reasons for exclusion 
Studies Exclusion 
Erekson, Yip [24] Did not specify readmission rate 
Tan, Kawamura [25] Did not specify readmission rate 
Finlayson, Zhao [26] Frailty tool not mentioned, frailty not 
an outcome of the study 
Choi, Yoon [27] Did not specify readmission rate 
George, Burke [28] Did not specify readmission rate as 
independent outcome 
Kenig, Mastalerz [29] Did not specify readmission rate 
Pujara, Mansfield [30] Did not specify readmission rate in 
frail patients 
Dale, Hemmerich [31] Did not provide a final frailty score 
[32] Did not specify readmission rate in 
frail patients 
 Neuman, Weiss [33] Frailty was not assessed 
 Fagard, Casaer [34] Did not specify readmission rate in 
frail patients 
Chen, Zhang [35] Did not specify readmission rate in 
frail patients 
Abt, Xie [36] Did not specify readmission rate in 
frail patients 
Hewitt, Moug [37] No cancer mentioned 
Badgwell, Stanley [38] Did not provide a final frailty score 
Ommundsen, Wyller [39] Only had frail patients 
Choe, Joh [17] Results for Frail and pre-frail patients 
were presented together 
Study characteristics  
The study characteristics are summarized on Table 2. Of the 4655 patients 
enrolled in the 9 studies (6 prospective [3, 40-44]) and 3 retrospective [20, 21, 
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45]), 73.6% (n=3354) were male and 26.4% (n=1229) were female, with an 
average of 70.1 years old. Six studies were performed in the USA [3, 20, 21, 40, 
44, 45], 1 in Norway [41], 1 in Japan [43] and 1 in Netherlands [42]. Frailty was 
defined using different frailty instruments, including the SOF Frailty index [17], the 
modified Frailty index [20, 21], sarcopenia [42, 43], Frailty index [3, 44] and Fried 
criteria [40]. Five articles addressed gastrointestinal cancer (3 studies for 
colorectal cancer [3, 42, 44], 1 for gastric cancer [17] and 1 for esophageal [43]), 
2 studies addressed gynecologic cancer (not specified [40] and endometrial 
cancer [45]), 1 study addressed bladder cancer [20] and 1 head and neck cancer 
[21]. None of the surgeries reported were emergency surgeries, and most of the 
studies were either only major surgeries or major surgery was the most common. 
However three studies reported minimally invasive surgery, one occurred in 19% 
of patients [40], one on 4% of the patients [45] and the other on 29% of the 
patients [41]. 
 
 
 
Table 2: Study Characteristics. 
Ref Year 
Countr
y 
Study Design Sample 
Age 
(mean) 
Gender 
Type of 
Cancer 
Stage of 
cancer 
Type of 
treatment 
Time of 
Postoperative 
readmission 
Courtney-
Brooks, 
Tellawi 
[40] 
2012 USA Prospective 37 73 
All 
Woman 
Gynecologic NA Surgery 
30-day 
readmission 
Chappidi, 
Kates [20] 2016 USA Retrospective 2679 69.65 
F: 513   
M:2166 
Bladder 
cancer 
NA Surgery 
30-day 
readmission 
Kristjanss
on, 
Nesbakken 
[41] 
2010 Norway Prospective 178 79.6 
M: 76 
F: 102 
Colorectal 
Stage0: 8 
Stage1-2: 100 
Stage3-4: 57 
Unclassified: 4 
Surgery 
30-day 
readmission 
Kuroki, 
Mangano 
[45] 
2015 USA Retrospective 122 65.9 
All 
Woman 
Endometrial 
Cancer 
Stage 1-2: 88 
Stage 3-4: 34 
Surgery, 
Radiation, 
Chemothe
rapy 
90-day 
readmission 
Robinson, 
Wu [3] 
2011 USA Prospective 60 75 
M: 58 F: 
2 
Colorectal 
Non-frail = 
Benign: 9 
Stage 1-2: 12 
Stage 3-4: 3 
Prefrail = 
Benign:3 
Stage 1-2: 5 
Surgery 
30-day 
readmission 
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Stage 3-4: 5 
Frail = 
Benign:7 
Stage 1-2: 12 
Stage 3-4: 4 
Robinson, 
Wu [44] 
2013 USA Prospective 72 74 NA Colorectal NA Surgery 
30-day 
readmission 
 Abt, 
Richmon 
[21] 
2016 USA Retrospective 1193 63.4 
M: 807 
F:386 
Head and 
Neack 
NA Surgery 
30-day 
readmission 
Lodewick, 
van 
Nijnatten 
[42] 
2014 
Netherla
nds 
Prospective 171 64 
M: 104 
F: 67 
Colorectal NA 
Surgery, 
chemother
apy, tumor 
ablation, 
preoperati
ve portal 
vein 
embolizati
on 
21 months 
(median, 1-90) 
readmission 
Makiura, 
Ono [43] 
2017 Japan Prospective 98 67 
M: 83 F: 
15 
Esophageal 
Total= stage0: 
1 stage1-2:57 
Stage3-4: 40 
Sarcopenia = 
stage0: 1 
Stage1-2:16 
Stage3-4:14 
No 
Sarcopenia= 
Stage0: 0 
Stage 1-2:41 
stage3-4:26 
 
Surgery, 
Neoadjuv
ant 
chemother
apy 
 
90-day 
readmission 
 
 
 
Table 2: Continuation 
Ref 
Frailty 
Tool 
Thresholds used to 
define frailty status 
Frailty Prevalence Postoperative readmisson 
n % n % Adjustment 
Courtney-
Brooks, 
Tellawi [40] 
Fried 
Not Frail: 0–1 
Intermediately frail: 
2–3 
Frail: 4–5 
Non- Frail: 21 
Prefrail: 10 
Frail: 6 
Non-Frail: 
28.7% Prefrail: 
13.6% 
Frail:8.2% 
Non-frail: 1 
Prefrail: 0 
Frail: 1 
Non-
Frail:4.7% 
Prefrail:0% 
Frail:16.6% 
NA 
Chappidi, 
Kates [20] 
Modified 
Frailty 
Index 
mFI >= 2 = Frail; mFI 
< 2 Non-frail 
Non-Frail 2019 
Frail: 660 
Non-Frail: 
75.3% 
Frail:24.7% 
Non-Frail: 
401 Frail: 137 
Non-Frail: 
19.8% 
Frail: 
20.75% 
NA 
Kristjansson, 
Nesbakken 
[41] 
CGA NA 
Non-frail = 21 
Prefrail = 81 
Frail = 76 
Non-
Frail:11.7% 
Prefrail:45.5% 
Frail:42.8% 
Non-
frail/Prefrail: 7 
Frail: 13 
 
Non-
frail/Prefrail
: 6.8% 
Frail: 
17.1% 
A separate logistic 
regression analysis looking 
at the 
predictive effect of frailty for 
severe complications for 
the 
subgroup colon cancer 
resulted in an odds ratio of 
3.71, with 
a 95% confidence interval 
of 1.74–7.88. For the 
subgroup 
17 
 
rectal cancer, the odds 
ratio was 2.0 with a 95% 
confidence 
interval of 0.61–6.56. 
Kuroki, 
Mangano 
[45] Sarcopeni
a 
Muscle mass below 
the median (\4.33 
cm2) on preoperative 
CT scan 
Non-Frail:61 
Frail: 61  
Non-Frail: 
50% Frail:50% 
Non-Frail: 4 
Frail: 3 
Non-
Frail:6.5% 
Frail:4.9% 
Adjusted multivariable 
model (HR, 1.57; 95 % CI, 
0.73–3.42; HRadj, 1.98; 95 
% 
CI, 0.81–4.86, 
respectively). 
Robinson, 
Wu [3] 
Frailty 
Index 
Non-frail: 0-1 
abnormal 
Characteristic; Pre-
frail: 2-3 abnormal 
characteristic; Frail: 
4-7 abnormal 
characteristics 
Non-Frail: 24 
Pre-Frail: 13 
Frail: 23 
Non-Frail:40% 
Pre-Frail: 
21.6% 
Frail: 38.3% 
 
Non-Frail:1 
Pre-Frail: 2 
Frail: 7 
 
Non-
Frail:4.1% 
Pre-Frail: 
15.3% 
Frail: 
30.43% 
 
ROC curves were 
performed, the area under 
the curve was compared 
with the 
null hypothesis in which the 
area is .5. The area equals 
.702 
(95% CI, .576 to .828; P 
5.004). 
Robinson, 
Wu [44] 
Frailty 
Index 
Non-frail: 0-1 
abnormal 
Characteristic; Pre-
frail: 2-3 abnormal 
characteristic; Frail: 
4-7 abnormal 
characteristics 
Nonfrail: 33 
Prefrail: 15 
Frail: 24 
Non-
Frail:45.8% 
Pre-Frail: 
20.8% 
Frail: 33.3% 
 
Non-frail: 2 
Prefrail: 3 
Frail: 7 
Non-
Frail:6% 
Pre-Frail: 
20% 
Frail: 
29.1% 
 
NA 
 Abt, 
Richmon [21] 
Modified 
Frailty 
Index 
Non-Frail mFI<=0.1 
Prefrail: mFI0.1-0.21 
Frail mFI>0.21 
Non-Frail: 922 
Prefrail: 206 
Frail: 65 
Non-
Frail:77.2% 
Pre-Frail: 
17.2% 
Frail: 5.4% 
 
Non-Frail: 47  
Prefrail: 12 
 Frail: 2 
Non-
Frail:5% 
Pre-Frail: 
5.8% 
Frail: 3% 
 
Independent 
variables included for 
adjustment during 
multivariable analysis 
were age, sex, body mass 
index (BMI), smoking 
status, 
American Society of 
Anesthesiologists’ 
classification,wound 
classification, currentwound 
infection, diabetes mellitus 
status, 
corticosteroid use for a 
chronic condition, operative 
time, 
history of previous 
operation within 30 days of 
surgery, operation 
year, and the consumption 
of more than 2 alcoholic 
drinks per day within the 
past 2 weeks. 
Lodewick, 
van Nijnatten 
[42] 
Sarcopeni
a 
Sarcopenia was 
defined as an L3 MI 
<41 cm2/m2 in 
women, <43 cm2/m2 
in men with a BMI 
<25, and <53 
cm2/m2 in men with 
a BMI >25 
Non-Frail: 91 
Frail: 80  
Non-Frail: 
53.2% 
Frail: 46.7% 
Non-Frail: 10 
Frail: 13 
Non-Frail: 
10.9% 
Frail: 
16.2% 
NA 
Makiura, 
Ono [43] 
Sarcopeni
a 
Low muscle mass 
was defined as \7.0 
kg/m2 for males and 
\5.7 kg/m2 for 
females. Low muscle 
strength was defined 
as a grip strength of 
\26 kg for males and 
\18 kg for females. 
Low physical 
performance was 
defined as a gait 
speed of\0.8 m/s. 
Non-Frail: 67 
Frail: 31  
Non-Frail: 
68.3% 
Frail: 31.6% 
Non-Frail: 11 
Frail: 12 
Non-Frail: 
16.4% 
Frail: 
38.7% 
Sarcopenia was a 
significant predictor of OS 
after adjustment for age, 
sex, and pathological stage 
(hazard ratio 2.35, 95% CI 
1.21–4.54; p = 0.01). 
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Prevalence of frailty and readmission 
Irrespective of the frailty assessment method, the average prevalence of 
frailty was 22.3% (range 5.4%–50%). Postoperative readmission was reported at 
30-days in 6 studies [3, 20, 21, 40, 41, 44], 90-days in 2 studies [43, 45], and 21 
months in 1 study [42]. Overall, prevalence of postoperative hospital readmission 
was 19% (range 5.4%–23.4%) in frail patients and 13.9% (range 4.1%–19.8%) in 
non-frail patients (Table 2).  
 
Risk of bias and applicability 
The overall quality of the studies had a good mean score of 7.7, out of 
these three studies were qualified as poor and the other 6 as good, with scores 
of a total from 6-9.  The results are shown in Table 3. 
Quality assessment 
Criteria 
Kristjansson 
S., et al. 
2010 
Chappidi 
et al. 
2016 
Robinson 
T, et al 
2011 
Robinson 
T, et al 
2013 
Brooks 
et al. 
2012 
Kuroki 
et al. 
2015 
Lodewick 
et al. 
2014 
Makiura 
2017 
Abt 2016 
Selection          
• Representatives of 
exposed cohort? 
* * * * * * * * * 
• Selection of the non-
exposed cohort? 
* * * * * * * * * 
• Ascertainment of 
exposure? 
* * * * * * * * * 
• Demonstration that 
outcome of interest 
was not present at 
start of study? 
* * * * * * * * * 
Comparability          
• Study controls for 
age/sex? 
       * * 
• Study controls for at 
least 3 additional risk 
factors? 
*  *   * * * * 
Outcome          
• Assessment of 
outcome? 
* * * * * * * * * 
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Table 3. Risk of bias. 
 
Primary outcome 
Pooled prevalence of frailty and pre-frailty frailty and the risk of 
readmission 
We explored the association between frailty and postoperative risk of 
readmission in cancer patients. Only 2 [41, 43] of the 9 studies showed a 
significant risk difference of postoperative hospital readmission between frail and 
non-frail patients (Figure 2). The pooled data showed that the risk of 
postoperative hospital readmission in the frail group was higher than the non-frail 
group (RR=1.58, 95% CI 1.07-2.33; P = 0.02) though with significant 
heterogeneity (p=0.05, and I2 = 54%). 
 
Figure 2: Forest plot for the association between frailty and the risk of 
readmission. 
• Was follow-up long 
enough for outcome 
to occur? 
* * * * * * * * * 
• Adequacy of follow-
up of cohorts? 
*   * * * * * * 
 
         
Overall Quality Score 
(max = 9) 
8 6 8 7 7 8 8 9 9 
Quality Good Poor Good Poor Poor Good Good Good Good 
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Subgroup analysis 
As depicted in Figure 2, we found highly heterogeneous results regarding 
the association between frailty and postoperative readmission. Therefore, the 
following subgroup analysis were performed to explore the sources of this 
heterogeneity:  by frailty status, follow-up period, frailty definition, type of cancer, 
and sample size (<100 vs >100). 
 
Frailty status and risk of readmission 
Figure 3 shows the subanalysis of the readmission risk by frailty status. 
For this analysis we divided the “non-frail” group in “robust” and “pre-frail” groups 
as explained in the methodological section. Comparison between frail and robust 
patients was possible to perform in 8 papers; between frail and pre-frail patients 
in 4 papers; and between pre-frail and robust patients in 4 papers. Frail patients 
were at greater risk of readmission than robust patients in 2 papers. Pooled 
analysis revealed a cumulative RR of 1.72 in frail patients (95% CI 1.02-2.89; 
P=0.04; I2=56%). No significant risk was found between pre-frail and frail patients 
(RR 1.31; 95% CI 0.62-2.77; P=0.48; I2=0%) or between pre-frail and robust 
patients (RR 1.35; 95% CI 0.78-2.34; P=0.29; I2=0%). 
A 
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Figure 3. Forest plot for subanalysis of the risk of readmission by frailty severity: 
a) frail vs. robust; b) frail vs. pre-frail; c) pre-frail vs. robust.  
 
 
 
 
 
 
 
 
 
 
B 
C 
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Frailty and risk of readmission by follow-up period  
Subgroup analysis was conducted according to time point of readmission after 
surgery (Figure 4). Five studies reported readmission data up to 30 days pos-
surgery and 4 studies above 30 days. Pooled analyses showed that there was 
no-significant risk ratio between the frail and non-frail patients for 30-days 
readmission (RR 1.28; 95% CI 0.81-2.02; p = 0.29; I2 = 39%). However, for 
readmission above 30 days (90 days to 7.5 years), there was a significant risk for 
frail in comparison to non-frail patients (RR 1.97; 95% CI 1.27-3.06; P = 0.003; I2 
= 11%). 
 
Figure 4: Forest plot for subanalysis of the risk of readmission by follow-up 
period. 
Frailty definition and risk of readmission  
Three different frailty tools formed sub analyses, the modified frailty index, 
sarcopenia and the frailty index. Comparing the two studies that utilized the 
modified frailty index, there was no show of significant risk difference between 
frail and non-frail patients (RR 1.04; 95% CI 0.87, 1.23; p = 0.69; I2 = 0%). With 
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sarcopenia there was no significant difference in three of the studies, the general 
analysis between the three studies did not show a significant risk for readmission 
for patients that were considered frail, though the values were very close to a 
significant risk (RR 1.70; 95% CI 1.01, 2.86; p = 0.05; I2 = 10%). The frailty index 
showed a significant risk difference between patients classified as frail and non-
frail and their readmission (RR 2.51; 95% CI 1.21, 5.19; p = 0.01; I2 = 0%). The 
general analysis between frailty tools showed no significant risk difference for 
patient readmission (RR 1.44; 95% CI 0.96, 2.14; p = 0.08: I2=47%), as shown 
on Figure 5. 
 
 
Figure 5: Forest plot by subanalysis of the risk of readmission by type of frailty 
tool. 
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Frailty and risk of readmission by type of cancer 
 The type of cancer that predominated between the different studies was 
digestive cancers (colorectal cancer and esophageal) and gynecologic cancer. 
The colorectal cancer sub-analysis showed a significant risk for frail patients for 
readmission (RR 2.16; 95% CI 1.48, 3.16; p < 0.0001; I2 = 0%), the gynecologic 
cancer did not show significant risk (RR 0.85; 95% CI 0.24, 3.06; p = 0.80; I2 = 
0%) (Figure 6). 
 
Figure 6: Forest plot by subanalysis of the risk of readmission by type of cancer. 
 
Frailty and risk of readmission by sample size 
Five studies presented a sample size over 100 patients, these did not show 
a significant increased risk for frail patients of hospital readmission (RR 1.18; 95% 
CI 0.83, 1.67; p=0.36; I2 = 25%). The studies with a smaller sample group, under 
100 patients showed a significant risk for frail patients of hospital readmission 
with a low heterogeneity between the studies (RR 2.49; 95% CI 1.52, 4.09; 
p=0.0003; I2 = 0%) (Figure 7). 
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Figure 7: Forest plot by subanalysis of the risk of readmission by sample size of 
study. 
 
Frailty and risk of readmission by type of treatment 
Treatment type showed a significant higher risk of readmission for frail 
patients when comparing the two group analysis (RR 1.58; 95% CI 1.07, 2.33; 
p=0.02; I2 = 49%), six studies reported on surgery as the only treatment plan but 
did not show a significant risk difference (RR 1.62; 95% CI 0.94, 2.78; p=0.08; I2 
= 54%) and the other three reported on surgery and other therapies, such as 
chemotherapy, radiotherapy, tumor ablation and preoperative portal vein 
embolization, also not resulting in a significant higher risk for frail patients (RR 
1.70; 95% CI 1.01, 2.33; p=0.05; I2 = 10%) (Figure 8).  
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Figure 8: Forest plot by subanalysis of the risk of readmission by type of 
treatment. 
 
Prospective and Retrospective studies and Frailty readmission 
Of the nine studies, 6 were prospective studies and showed a high 
significant risk difference for readmission for frail patients (RR 2.20; 95% CI 1.51, 
3.20; p<0.0001; I2 = 0%). The other 3 studies did not have a significant risk 
difference for readmission (RR 1.03; 95% CI 0.87, 1.22; p= 0.72; I2 = 0%), the 
overall analysis between both groups also showed a significant risk for frail 
patients and hospital readmission (Figure 9).  
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Figure 9: Forest plot by subanalysis of the risk of readmission by type of study 
design. 
Sensitivity analysis and publication bias 
When selected articles were individually removed and the effect size 
recalculated, the sensitivity analysis illustrated that there was significant change 
of the results (Table 4).  
Table 4: Sensitive analysis 
 
 
 
 
 
 
Author Risk Ratio Heterogenity p 
Abt 2016 1.70 [1.13, 2.55] 54% 0.01 
Chappidi 2016 1.90 [1.34, 2.70] 0% 0.0004 
Courtney-Brooks 2012 1.54 [1.04, 2.28] 51% 0.03 
Kristjansson 2010 1.48 [0.99, 2.20] 45% 0.05 
Kuroki 2014 1.67 [1.10, 2.53] 54% 0.02 
Lodewick 2014 1.62 [1.03, 2.55] 54% 0.04 
Makiura 2017 1.45 [0.98, 2.16] 39% 0.06 
Robinson 2011 1.53 [1.01, 2.30] 50% 0.04 
Robinson 2013 1.48 [1.00, 2.19] 45% 0.05 
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Publication bias was assessed by visual inspection of the funnel plot 
(Figure 10), which we considered low.  
 
 
Figure 10: Funnel Plot for publication bias 
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DISCUSSION 
We conducted this meta-analysis and systematic review with the intent to explore 
the association between frailty and the risk of post-surgery hospital readmission 
in cancer patients. Our data points that frailty is associated with greater risk of 
readmission and subanalysis suggest that this is influenced by the type of 
assessment tool, type of cancer, study design and sample size. 
Summary of evidence  
Several studies support that that frailty is a stronger predictor of 
postoperative outcomes compared with several classic surgical risk‐assessment 
tools [14-16]. Recently, it was also suggested that frailty might be also useful to 
predict unplanned readmission and [3, 17, 18]. Readmissions are associated with 
lower survival and can result in the delay in receipt, or cancellation, of adjuvant 
treatment, thus altering the progression of the disease [46]. Thus, an effort to 
study the risk factors for readmissions is mandatory, as well as to identify and 
intervene on preventable causes. Frailty seems to be a risk factor for future 
readmission after surgery, as supported by one meta-analysis in adult population 
after elective major abdominal surgery [47]. However, that indication was based 
on a secondary analysis and not all patients submitted to surgical procedures 
were performed for cancer [47]. In our review of 9 observational studies, including 
4655 patients, frailty was present in 22.3% (raged from 5.4% to 50%) of all cancer 
patients undergoing surgery, which is in accordance with the numbers of previous 
reports for this clinical population [13]. We found an association with increased 
risk of readmission after surgery for patients classified as frail. As far as we are 
aware, this is the first meta-analysis specifically addressing this question in 
cancer patients. Patient readmissions can be caused by multiple causes. A recent 
analysis of the US Nationwide Readmissions showed that the most common 
cause of a readmission after complex cancer surgery was infection (26.5%) 
followed by other GI complications (17.2%), respiratory conditions (9.5%), and 
dehydration/acute renal failure/electrolyte imbalances [46]. Other causes of 
readmission were reported in the literature regarding the post-surgery period, 
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however without specification if they were the reasons for readmission after 
hospital discharge. It included respiratory complications, cardiovascular 
complications, neurologic complications, renal complications, reoperation, blood 
transfusion, bowl reconstruction, thromboembolism, wound infection, sepsis, 
gastro-intestinal complications and hematological complications [20, 42, 44, 45]. 
We found significant heterogeneity and thus performed several 
subanalysis. The association between frailty and risk of readmission was lost 
when we pooled the data by severity of frailty, 30-day follow-up period and type 
of treatment. This surprising result can be explained, at least in part by the fact 
that frail patients have more complications and stay longer in the hospital to 
manage them [48]; and frail patients are at higher risk of short and long-term 
death [48, 49], which means that the total number of frail patients in risk of 
readmission is probably lower than the non-frail.  When the same was performed 
for the type of frailty test, only frailty as defined by the Frailty Index had increased 
risk of readmission. This should not be interpreted as if Frailty Index is a good 
predictor of the risk of readmission because the 2 studies [3, 44] supporting that 
effect are from the same group and thus can be biased. Moreover, when 
stratification of data was performed by type of cancer, we observed that frail 
patients submitted to surgery because of digestive cancer (but not gynecologic) 
were at high risk. Future studies should address if these differences are due to 
cancer-specific issues (e.g. cachexia) or surgery-specific (e.g. caused by 
malabsorption of nutrients and dehydration) which are more prevalent in digestive 
cancers [50]. The greater risk of readmission in frail patients is also supported by 
prospective studies (which were mainly low-sample size) but not by retrospective 
studies. This can be explained by the fact that retrospective studies usually obtain 
their data through historical records and relevant information might be missing 
(leading to poor classification) or was introduced by different persons (leading to 
more subjectivity). 
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Limitations 
There are few studies addressing the association of frailty and patient 
readmission after cancer surgery. In addition, the ones that exist only poorly 
reported the reasons for readmission.  
 
CONCLUSIONS 
Frailty was associated with a higher risk of readmission after cancer 
surgery. Special attention should be paid to patients with high risk factors, such 
as frail patients, during the postoperative follow-up and recovery periods. 
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Study 2: The Comparison of Prevalence and Agreement Between 
Different Frailty Assessment tools in Oncologic Patients 
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ABSTRACT: 
 
Objectives: The aim of this study was to compare the prevalence and agreement 
between 5 widely used frailty instruments in patients with cancer undergoing 
surgery.  
Methods: Patients with gastrointestinal cancer and head and neck cancer were 
recruited at the IPO-Porto. Frailty was assessed with the Vulnerability Elders 
Survey-13 (VES-13), Phenotypic Frailty (FP), 8 Foot up-and-go (8FuG), 5 m gait 
speed and the handgrip test to assess frailty. We compared the prevalence of 
frailty and the concordance between the different tests.  
Results: We were able to recruit 166 patients, 53.3% of patients had 
gastrointestinal cancer and 46.7% head and neck cancer. Patients’ mean age 
was 61.8±11.50 years old, and 77% (n=128) were male, mean weight was 69.1 
±15.84 kg and 5.3% were underweight, 35.5% were classified as pre-obese and 
18.1% as obese. Frailty prevalence was 37.3%, 25.9%, 20.49.4% 8.2% as 
assessed by hand grip, VES-13, FP, 5m gait speed and 8 foot up and go, 
respectively. A small-moderate correlation and concordance was found between 
the instruments.  
Conclusions: Different frailty instruments lead to different estimates of frailty and 
present little concordance even within the same population. 
 
 
 
 
 
 
Keywords: FRAILTY, ONCOLOGIC PATIENTS, PREVALENCE, AGREEMENT  
 
36 
 
 
 
37 
 
INTRODUCTION 
 For the majority of cancer types, the incidence and mortality by cancer 
increase as we age, with a tendency of leveling off in the very old ages [51, 52]. 
With the increase in life expectancy that our society is experiencing nowadays, it 
is anticipated that the overall incidence of cancer will continue to rise and will 
impose a significant burden [53]. According to the current projections, the number 
of older adults above the age of 65 years will double by 2050, leading to a nearly 
50% increase in the annual cancer incidence [7]. Because surgery is the only 
curative option for solid cancers, particularly in early stage disease, it is also 
evident that the number of cancer patients requiring surgical treatment will 
increase. In 2015, from the 15.2 million individuals diagnosed with cancer 
worldwide, 80% required surgery, and this number is predicted to rise to 45 million 
by 2030 [7]. Despite the advances in surgical procedures and perioperative 
management, surgery is not free of risk for morbidity and mortality, particularly in 
the geriatric patient [7]. This often results in geriatric patients being refused 
surgery, as they are believed to be have poor tolerance to surgical stress and 
thus, to be at increased risk of postoperative morbidity and mortality [54]. 
However, it is becoming clear that older adults are very heterogeneous and the 
risk of adverse postoperative outcomes is not adequately described by 
chronological age, comorbidities, or the type of surgical procedure alone [55], 
which is traditionally used to assess the patient's “fitness” for surgery [1]. 
Frailty is increasingly recognized as a valuable measure for the 
preoperative assessment of patients submitted to surgery in different settings 
such as vascular [56], cardiac [57] orthopedic [58] and cancer [13]. This 
syndrome is characterized by a decline in the reserve of multiple physiological 
systems, decreasing tolerance to stresses such as disease or surgery, typically 
linked with advanced age, nevertheless younger patients can also be classified 
as frail [1]. More than 50% of geriatric cancer patients have pre-frailty or frailty 
and are at increased risk of chemotherapy intolerance, postoperative 
complications and mortality [13]. Of note, it has been demonstrated that frailty is 
a stronger predictor of postoperative outcomes compared with several classic 
surgical risk‐assessment tools [14-16]. After determining the frailty status, the 
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clinician can provide a tailored intervention to optimize the patient before surgery, 
for instance through prehabilitation programs [59] and thus increase tolerance to 
surgical stress and reduce the occurrence of adverse outcomes [60-62]. 
 Despite the negative consequences of frailty are well-established, 
clinicians will find tremendous difficulties when choosing an instruments as a gold 
standard measure of frailty does not exist and a wide range of frailty instruments 
are used [63]. Moreover, there are no consensus on which frailty assessment 
instrument is appropriate to a specific purpose (e.g. risk of morbidity and 
mortality), context (e.g. community, primary or secondary care, critical care) [64]. 
Importantly, there is scarcity of studies comparing the agreement between frailty 
instruments, which is fundamental to compare data from different studies and to 
facilitate the choice for future research or use in the clinical setting. This is very 
important as it has been shown that different instruments provide different frailty 
prevalence (and thus risk profile estimation) when tested in the same population 
[65, 66]. Thus, the purpose of this work was to compare the prevalence and 
agreement between 5 widely used frailty instruments in patients with cancer 
undergoing surgery: the Vulnerability Elders Survey-13 (VES-13), Phenotypic 
Frailty (FP), 8 Foot up-and-go (8FuG), 5 m gait speed and the handgrip test. 
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METHODS 
 
Study design  
 
This is an observational cross-sectional study.  
 
Setting and participants 
Participants were recruited at the Portuguese Oncology Institute of Porto 
(IPO-Porto), every Monday, in the Gastrointestinal and the Head and Neck wing, 
between December 2018 and June 2019. Data was collected in all the patients 
fulfilling our inclusion criteria that agreed to be a part of the study.  
Inclusion criteria for patients was to be over 18 years old, to be diagnosed 
with cancer that required a surgery procedure and to be able to answer the 
questioners in Portuguese or English. Any patients not meeting the inclusion 
criteria were excluded from the study.  
 This work has been approved by the ethical committee of the IPO-Porto 
(Comissão de Ética Para a Saúde do Instituto Português de Oncologia do Porto 
Francisco Gentil, E.P.E. (Doc. CES-IPOP 03)), institution where it was developed 
and all the subjects gave their informed consent (Appendix I) and received an 
information sheet briefly explaining the study (Appendix II).   
 
Measurements 
Information regarding demographics (age, gender, education level, marital 
status), anthropometry [weight, height, body mass index (BMI)], and cancer type 
were collected (Apendix III). The weight was measured using a digital scale 
(Tanita Inner Scan BC 532), patients were asked to stand on the scale without 
shoes and coats, with help when necessary to get on the scale. Height was 
measured using a stadiometer (Seca 213), patients were placed with their backs 
to the stadiometer looking forward and the measures were checked twice, a third 
time if there was a difference between the two previous measurements. Body 
mass index was calculated using the weight and the height with the formula BMI 
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= kg/m2, being kg the weight of the patient in kilograms and m2 patient height in 
meters squared. 
Frailty was assessed by different tools, including FP, VES-13, 8FuG, 5 m 
gait speed and the handgrip test. These tests have been previously validated in 
cancer patients [1], and have shown to predict risk of adverse health outcomes, 
post-operative complications and mortality outcomes [1, 63, 67, 68]. 
 
Frailty assessment 
 
The Vulnerability Elders Survey-13 
 The vulnerability Elders Surgey-13, or VES-13, is a questionnaire divided 
into four categories to evaluate age, health auto-perception, physical impairment 
and disabilities. The questions involve the ability to perform specific activities 
including, crouching/kneeling, carrying heavy objects (approximately 5kgs), 
extending arms over shoulder level, precision to handle small objects, resistance 
to walk 500m, heavy housework chores and difficulties to perform daily tasks due 
to health concerns. Answers were scored 1 point due to impairments and a sum 
of the points resulting into a score ≥3 classified patients as “frail” [69]. This 
questionnaire was already validated for identification of frailty in our population 
[70] and was shown to predict risk of mortality, medical care institutionalization 
and disability [71].  
 
8 Foot Up-and-go 
This is a feasible test that has been used for oncologic and non-oncological 
patients [72]. The test consists of patients being timed, in seconds, from the 
moment they stand from a chair, walk 2.44m and return to the chair to sit back 
down. The patient is categorized as “frail” if spending ≥15s to perform the test, 
“pre-frail” if 11-14s and “robust” if ≤10s [72]. For the purpose of this study, “pre-
frail” and “robust” were grouped to form the “non-frail” to allow comparison with 
other tests that only allow dichotomization of frailty.  
 
Phenotypic Frailty  
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The phenotypic frailty assessment considers 5 domains (shrinking, 
weakness, exhaustion, gait speed and physical activity), evaluated as follows:  
• Shrinking: unintentional weight loss of ≥ 4.5 Kg in prior year OR 
unintentional weight loss of at least 5% of previous year's body 
weight [73]; 
• Weakness: grip strength was assessed with a dynamometer (Takei 
5401 Digital Dynamometer), adjusted for gender and body mass 
index; Each patient performed 3 measures, and the average of 
them was considered the patients final score, to be adjusted 
according to gender and body mass index (BMI). Thus, frailty 
should be considered for this criterion if [73]:  
o Men: BMI ≤ 24 and ≤29 Kg; BMI 24.1–26 and ≤30 Kg; BMI 
26.1–28 and ≤30 Kg; BMI > 28 and ≤32 Kg 
o Woman: BMI ≤ 23 and ≤17 Kg; BMI 23.1–26 and  ≤17.3 Kg; 
BMI 26.1–29  e ≤18 Kg; BMI > 29 and ≤21 Kg 
 
• Poor endurance and energy: as indicated by self-report of 
exhaustion. Self-reported exhaustion, identified by two questions 
from the Centers for Epidemiologic Studies Depression (CESD) 
scale. Subjects were asked: How often in the last week did you feel 
like everything you did was an effort? How often in the last week did 
you feel like you cannot get going? Answers include: 0= rarely or 
none of the time (≤1 day), 1= some or a little of the time (1–2 days), 
2= a moderate amount of the time (3–4 days), or 3= most of the 
time. Subjects answering “2” or “3” to either of these questions are 
categorized as frail by the exhaustion criterion [73]; 
• Slowness: Gait speed was assessed by measuring the time the 
patient took to complete a 5m course. Score was as follows [73]: 
Men Height ≤ 173 cm and time ≥ 7.14 s = 1; Men Height > 173 cm 
and time ≥ 6.57 s = 1; Woman Height ≤ 159 cm and time ≥ 7.14 s = 
1; Woman > 159 cm and time ≥ 6.57 s = 1; 
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• Low physical activity level: A weighted score of kilocalories 
expended per week. Physical activity levels were obtained with the 
International Physical Activity Questionnaire short form (IPAQ-SF) 
[74]. Total energy expenditure (Kcal/week) was calculated as 
follows: time spent on each physical activity category (in hours) x 
corresponding MET value x weight (kg). Male subjects with total 
energy expenditure (kcal/week) ≤383 are classified as “frail”. 
Female subjects with total energy expenditure (kcal/week) ≤270 are 
classified as “frail” [73]. 
 
 
Frailty classification is performed according to the overall summation of 
deficits presented in the 5 domain as follows: “robust” if “0”, “pre-frail” if “1-2” and 
“frail” if “≥3” deficit [73]. The phenotypic frailty assessment has been validated 
and used in oncological setting, being a predictor of mortality and postoperative 
complications [75, 76]. 
 
Gait speed  
Gait speed was assessed as part of the PF assessment (described above), 
but is also used as a single test to assess frailty [1] and was shown to be a good 
predictor of morbidity and mortality in older patients undergoing cardiac surgery 
[77]. 
 
Handgrip Test 
Handgrip test was assessed as part of the PF assessment (described 
above), but is also used as a single test to assess frailty [1, 78, 79]. 
 
 
Statistical Methods 
Statistical analysis was performed using the IBM SPSS 25 software 
(SPSS, USA). Normal data distribution was examined by the Kolmogorov-
Smirnov test. Categorical data are reported as absolute values and percentages, 
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and continuous data as mean±standard deviation. Between gender comparisons 
were performed by independent t-test and chi-square test as appropriated. 
Pearson’s correlation was used to analyze the relationship between frailty tools 
and Kappa Cohen for concordance analysis. Agreement was interpreted as poor, 
slight, fair, moderate or substantial, if Kappa value was 0.0, 0.20, 0.40, 0.60, 0.80 
or 1.0, respectively [80]. Statistical significance was established for p<0.05. 
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RESULTS 
 
Participants  
We were able to recruit a total of 166 patients, 88 from gastrointestinal 
aisle and 77 from the head and neck aisle. The demographic characteristics are 
presented in Table 1. Patients’ mean age was 61.8±11.50 years old, and 77% 
(n=128) were male. Overall, mean weight was 69.1 ±15.84 kg and, according to 
BMI, 5.3% were underweight, 35.5% were classified as pre-obese and 18.1% as 
obese. 
Table 1: General characterization of the sample. 
  
 Total  
(n=166) 
Men  
(n=128) 
Women 
(n=38) 
p 
 
Age (Years) 61.8 ±11.50 61.9 ±10.76 61.3 ±13.85 0.794 
Weight (Kg) 69.3 ±15.27 69.1 ±15.84 69.9 ±13.37 0.803 
Height (m) 1.64 ±0.07 1.66 ±0.06 1.56 ±0.06 0.000 
BMI <18,5 9 (5.4) 9 (100) 0 (0) 
0.001 
18.5 – 24.9 68 (41) 57 (83.8) 11 (16.2) 
25 - 30 59 (35.5) 47 (79.7) 12 (20.3) 
>30 30 (18.1) 15 (50) 15 (50) 
Place_assessment, 
n (%) 
Gastrointestinal 88 (53.3) 62 (70.5) 26 (29.5) 0.340 
Head and Neck 77 (46.7) 65 (84.4) 12 (15.6) 
Marietal_status, n 
(%) 
Single 11 (6.7) 9 (81.8) 2 (18.2) 0.653 
Married 117 (71.3) 90 (76.9) 27 (23.1) 
Divorced 17 (10.4) 14 (82.3) 3 (17.7) 
Widow 17 (10.4) 11 (64.7) 6 (35.3) 
Other 2 (1.2) 2 (100) 0 (0) 
Education, n (%) Basic 1o 86 (52.1) 66 (76.7) 20 (23.3) 0.020 
Basic 2o 31 (18.8) 27 (87) 4 (13) 
Basic 3o 14 (8.5) 11(78.5) 3 (21.5) 
Secondary 16 (9.7) 13 (81.2) 3 (18.8) 
No education 9 (5.5) 8 (88.8) 1 (11.2) 
Higher Degree 9(5.5) 3 (33.3) 6 (66.7) 
M= metres; BMI= Body mass índex 
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Prevalence of individual frailty markers by frailty test 
Table 2 shows the distribution of positive frailty markers on each domain 
of each instrument. Based on Fried’s criteria, patients on the frail category had 
frequent weakness (37.3%), physical activity (42.8%), shrinking (36.7%), gait 
speed (9.4%) and exhaustion (22.9%). According to VES-13, frail patients mainly 
reported poor health auto-perception (45.8%) and physical impairment (35.5%). 
Age had the lowest prevalence of frailty (1.8%) and disabilities presented the 
second lowest (14.5%). The domain that had the least patient frailty was gait 
speed, 38.7% of frail patients on the Fried classification presented a low score 
for gait speed, the highest was weakness were 93.5% of frail patients had a low 
score on the weakness domain.  
 
Table 2: Distribution of positive frailty markers. 
 
 
 
 
 
 
 
 
 
 
 
 
Ves-13=The Vulnerability Elders Survey; 5m= 5m Gait speed; Fried= Phenotypic Frailty test 
 
 
 
 
 Total 
(n,%) 
Frail 
(n, %) 
Non-frail 
(n,%) 
Fried 
Shrinking 61 (36.7) 25 (73.5) 36 (27.3) 
Weakness 53 (37.3) 29 (93.5) 24 (21.6) 
Exhaustion 38 (22.9) 21 (61.8) 17 (12.9) 
Gait speed 15 (9.4) 12 (38.7) 3 (2.3) 
Physical Activity 71 (42.8) 29 (85.3) 42 (31.8) 
 
 
 
VES13 
Age 3 (1.8) 2 (4.7) 41(95.3) 
Health auto-
perception 
76 (45.8) 35 (81.4) 8 (18.6) 
Physical Impairment 59 (35.5) 38 (88.4) 5 (11.6) 
Disabilities 24 (14.5) 24 (55.8) 19 (44.2) 
8 Foot Up 
and go 
 
13 (8.2)   
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Prevalence of frailty by frailty test 
Figure 1 shows the prevalence of frail and non-frail patients by gender, 
according to each frailty definition. As it is possible to observe, the prevalence of 
frailty differed between each instrument, with frailty as defined by the handgrip 
presenting the highest prevalence (37.3% of patients), followed by  VES-13 
(25.9%), FP (20.4%), 5m gait speed (9.4%) and 8 foot up and go (8.2%). Frailty 
prevalence was men had a higher result than in woman, 14.5% of frail patients 
were men on Fried, while woman prevalence was 6%, on VES-13 19.3% of frail 
patients were men and 6.6% woman, Up and go 19% were man and only 3.8% 
were woman. The highest prevalence was on the Handgrip test, with 26.1% of 
frail patients were man and 11.3% woman and the lowest prevalence was on the 
5m Gait speed, only 5.7% of patients were man and 3.8% woman were classified 
as frail, with a total of 9.5% of patients classified as frail.  
 
 
Figure 1: Prevalence of frailty among different tools. 
 
VES-13=The Vulnerability Elders Survey; 5m= 5m Gait speed; Fried= Phenotypic Frailty test; 
Weakness= Handgrip Test 
0,0%
10,0%
20,0%
30,0%
40,0%
50,0%
60,0%
70,0%
80,0%
Nonfrail Frail Nonfrail Frail Nonfrail Frail Nonfrail Frail Nonfrail Frail
Fried VES13 up and go Weakness 5m
Male Female
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Table 3: General patient’s characteristics by frailty tool. 
 
Ves-13= The Vulnerability Elders Survey; 5m= 5m Gait speed; Fried= Phenotypic Frailty test; BMI= Body mass index 
  Fried Ves-13 Up and go Handgrip 5m 
  Nonfrail Frail p Nonfrail Frail p Nonfrail Frail p Nonfrail Frail p Nonfrail Frail p 
Total (n,%)  132 (79.5) 34 (20.5)  123 (74.1) 43 (25.9)  145 (91.8) 13 (8.2)  89 (62.7) 53 (37.3)  144 (90.6) 15 (9.4)  
Age (Years) 60.5 ±11.2 67.2 ± 11 0.002 59.7 ±10.6 67.7±11.9 0.000 60.2±10.5 78.4 ±7.6 0.000 59 ± 11.2 66.7 ± 11 0.000 
60.6 ± 
10.9 
73.5±11.9 0.000 
Weight (kg) 70.5 ±15.4 64.9 ±14.3 0.062 70.9 ±16.3 64.7±10.4 0.005 69.4±15.6 72.5±12.7 0.489 72.2±15.9 65 ±12.6 0.006 
69.6 ± 
15.5 
67.1 ±13.4 0.559 
Height (m) 
1.65 ± 
0.07 
1.61 ± 0.08 0.010 
1.65 ± 
0.07 
1.61 ±0.07 0.010 1.64 ±0.07 1.60 ±0.10 0.042 1.65 ±0.07 1.60 ±0.07 0.000 1.64 ±0.07 1.59 ±0.08 0.006 
BMI (n,%) 
<18,5 6 (3.6) 3 (1.8) 
 
 
 
0.792 
7 (4.2) 2 (1.2) 
 
 
 
0.614 
8 (5.1) 0 (0) 
 
 
 
0.011 
3 (2.1) 2 (1.4) 
 
 
 
0.852 
8 (5) 0 (0) 
 
 
 
0.650 
  
18,5 - 24,9 54 (32.5) 14 (8.4) 49 (29.5) 19 (11.4) 63 (39.9) 2 (1.3) 35 (24.6) 24 (16.9) 61 (38.4) 6 (3.8) 
25 – 30 48 (28.9) 11 (6.6) 42 (25.3) 17 (10.2) 47 (29.7) 8 (5.1) 35 (24.6) 17 (12) 49 (30.8) 7 (4.4) 
>30 24 (14.5) 6 (3.6) 25 (15.1) 5 (3) 27 (17.1) 3 (1.9) 16 (11.3) 10 (7) 26 (16.4) 2 (1.3) 
Place of 
Assessment 
(n,%) 
Digestives 70 (79.5) 18 (20.5) 
 
0.959 
67 (76.1) 21 (23.9)  
 
0.492 
75 (87.2) 11 (12.8)  
 
0.024 
45 (59.2) 31 (40.7)  
 
0.396 
75 (88.2) 10 (11.7)  
 
0.293  
Head and Neck 61 (79.2) 16 (20.8) 55 (71.4) 22 (28.6) 69 (97.1) 2 (2.9) 43 (66.1) 22 (33.9) 68 (93.1) 5 (6.9) 
Marietal 
status (n,%) 
Single 9 (5.5) 2 (1.2) 
 
 
 
0.054 
9 (5.5) 2 (1.2) 
 
 
 
0.014 
11 (7) 0 (0) 
 
 
 
0.000 
8 (5.7) 2 (1.4) 
 
 
 
0.017 
11 (7) 0 (0)  
 
 
0.000 
  
Married 96 (58.5) 21 (12.8) 93 (56.7) 24 (14.6) 109 (69.4) 6 (3.8) 70 (50) 33 (23.6) 108 (68.8) 6 (3.8) 
Divorced 15 (9.1) 2 (1.2) 12 (7.3) 5 (3) 14 (8.9) 0 (0) 6 (4.3) 6 (4.3) 13 (8.3) 2 (1.3) 
Widow 9 (5.5) 8 (4.9) 7 (4.3) 10 (6.1) 8 (5.1) 7 (4.5) 4 (2.9) 10 (7.1) 9 (5.7) 6 (3.8) 
Other 2 (1.2) 0 (0) 1 (0.6) 1 (0.6) 2 (1.3) 0 (0) 0 (0) 1 (0.7) 2 (1.3) 0 (0) 
Education 
(n,%) 
Basic 1o 65 (39.4) 21 (12.7) 
 
 
 
 
0.456 
57 (34.5) 29 (17.6) 
 
 
 
 
0.015 
74 (47.1) 8 (5.1 
 
 
 
 
0.013 
42 (29.8) 31 (22) 
0.177 
72 (45.6) 9 (5.7)  
 
 
0.005 
 
 
  
Basic 2o 26 (15.8) 5 (3) 26 (15.8) 5 (3) 29 (18.5) 1 (0.6) 22 (15.6) 7 (5) 30 (19) 1 (0.6) 
Basic 3o 10 (6.1) 4 (2.4) 14 (8.5) 0 (0) 13 (8.3) 0 (0) 5 (3.5) 7 (5) 13 (8.2) 0 (0) 
Secondary 14 (8.5) 2 (1.2) 12 (7.3) 4 (2.4) 15 (9.6) 0 (0) 9 (6.4) 3 (2.1) 14 (8.9) 1 (0.6) 
No education 7 (4.2) 2 (1.2) 5 (3) 4 (2.4) 5 (3.2) 3 (1.9) 5 (3.5) 3 (2.1) 5 (3.2) 4 (2.5) 
Higher Degree 9 (5.5) 0 (0) 9 (5.5) 0 (0) 9 (5.7) 0 (0) 6 (4.3) 1 (0.7) 9 (5.7) 0 (0) 
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Characterization of the sample by frailty level  
 
Table 3 shows the general characteristics of the sample by frailty level, as 
assessed by each instrument. On the handgrip test 29 patients weren’t able to do 
the test, either due to problems with the handgrip dynamometer or to physical 
difficulty. 12 patients weren’t able to complete the 5m test and 13 the up and go 
test due to mobility difficulty, and 5 patients didn’t complete the Fried or VES-13 
test. The total of frail patients varied from 13 (8.2%), on the Up and go, to 53 
(37.3%) on the Handgrip test. Lowest BMI scores for frail patients were found on 
Fried, with only 3 (1.8%) frail patients presented a low BMI, while the highest BMI 
results, classifying patients as obese, was found on the handgrip test, were 10 
(7%) of patients were frail. The highest number of frail patients for both cancer 
types were classified as frail on the handgrip test, 31 (40.7%) of digestive patients 
were classified as frail and 22 (33.9%) of head and neck cancer patients were 
classified as frail.  
 
Relationship between different frailty tools 
The bivariate correlation between frailty tools was analyzed with the 
Pearson correlation (Table 4). No test had a strong positive correlation, but all 
had a significant correlation, the strongest correlations were between Fried and 
the Handgrip test and the 5m and the Up and go, both with r = 0.673.  
 
Table 4: Bivariate correlation between frailty instruments. 
 
Fried VES- 13 Up and go Handgrip 
r p r p r p r p 
 
VES-13 0.292 0.000 
 
 
 
Up and go 0.318 0.000 0.441 0.000 
Handgrip 0.673 0.000 0.176 0.036 0.363 0.000 
5m 0.421 0.000 0.374 0.000 0.673 0.000 0.384 0.000 
r = Pearson correlation; Ves-13 The Vulnerability Elders Survey; 5m= 5m Gait speed; Fried= 
Phenotypic Frailty test 
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The Kappa Cohen was used to measure the agreement between the 
different frailty tools, as shown in Table 5. All tests had a significant result, Fried 
had a moderate agreement with the handgrip test and with the 5m, indicating a 
moderate similarity between patient frail classification. All the other analyses 
presented a weak agreement between, showing a low similarity between the 
results, suggesting that different patients were classified as frail when using 
different instruments.  
Table 5: Agreement between frailty instruments. 
 Fried VES- 13 Up and go Handgrip 
 K p K p K p K p 
VES-13 0.209 0.007   
  
  
Up and go 0.142 0.000 0.153 0.000 
Handgrip 0.573 0.000 0.165 0.360 0.090 0.001 
5m 0.452 0.000 0.324 0.000 0.350 0.000 0.281 0.000 
K=kappa coefficient; Ves-13= The Vulnerability Elders Survey; 5m= 5m Gait speed; Fried= 
Phenotypic Frailty test 
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DISCUSSION 
The purpose of this work was to compare the prevalence and agreement 
between 5 widely used frailty instruments in patients with cancer undergoing 
surgery: the Vulnerability Elders Survey-13 (VES-13), Phenotypic Frailty (FP), 8 
Foot up-and-go (8FuG), 5 m gait speed and the handgrip test. Our data suggest 
that prevalence of frailty varied widely between these instruments, and their 
agreement was limited. 
Despite the advances in surgical procedures and perioperative 
management, surgery is not free of risk for morbidity and mortality, particularly in 
the geriatric patient [1, 3, 7]. frailty is a stronger predictor of postoperative 
outcomes compared with several classic surgical risk‐assessment tools [14-16]. 
Despite that, as a gold standard measure of frailty does not exist, there are 
several instruments available and each instrument has its upside and downsides 
features, which might be an obstacle in terms of deciding which should be used 
for what. The data from our study shows that the choice of the instrument is not 
straightforward, as frailty prevalence ranged from 8.2 to 37.3% depending on the 
assessment tool. This notion is in accordance with the results from other authors 
who showed similar findings with these and other instruments [65, 66]. [4, 71]. 
This is a concern that needs to be taken into account when basing clinical 
decisions on frailty assessment, as it may lead to inaccurate risk profile 
estimation. 
  
In addition, we showed that VES-13, FP, 8FuG, 5 m gait speed and the 
handgrip test had poor correlation and agreement. This limited agreement has 
also been confirmed by other studies comparing different frailty tools but some 
showed positive results. For instance, the Balducci frailty criteria, Fried and VES-
13 had poor concordance also with oncologic patients [81] while low-moderate 
agreement was reported in relation to FP, the Frailty Index and with the 5m Gait 
speed in geriatric patients in primary care [4].  However a moderate-strong 
correlation and a close agreement was between Fried, the Deficit Index, the 
Edmonton frailty, the clinical frailty scale, the Derby frailty index and the acute 
frailty network frailty criteria, in patients with chronic heart failure, indicating that 
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though each assessment method consists of different components, they can 
result into a common outcome [82]. The difference between these and the 
previous studies could be due to the assessment tools analyzed, sample size, 
different clinical populations. Thus, more than adding new frailty scales to the 
existing one, it will be important to test agreement of the existing ones, 
understand the factors underlying such discrepancies. Importantly, it is 
mandatory to compare their diagnostic accuracy for specific adverse outcomes, 
which need to be the point of reference when defining the standard instrument. 
 
Limitations, strengths, and future perspectives 
This is a single-center study conducted in IPO-Porto with a limited sample 
size for each cancer type, an external validation from other populations with a 
different health care system could be useful to improve the analyses. Data was 
collected exclusively on Mondays, limiting the extrapolation of our data to other 
patients with same cancer type treated in IPO-Porto. Also, only a small 
percentage of participants were female. Due to time constrains of finishing this 
work, we were unable to collect information regarding risk factors, comorbidities, 
location of cancer and its severity, which has to be collected by hand on physical 
files. Despite these limitations, this is to our knowledge the first study to compare 
FP, Ves-13, Up and go, 5m Gait speed and Handgrip test, in the same population 
of cancer patients for head and neck and gastrointestinal cancer. Further studies 
are needed to compare the frailty classification with other tools, perform patient 
follow-up to record different adverse outcomes and check which tools had better 
prediction agreement for that specific outcome. If accuracy and agreement can 
be found between a single-item test and complex / time-consuming tool, it will 
eventually be an optimal option for hospital implementation.  
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CONCLUSION 
 
Our results suggest that Fried, VES-13, 5m gait speed, Up and go and Handgrip 
categorize different patients as frail or non-frail. This finding emphasizes the need 
for consensus on the definition of frailty, requiring further work to optimize the 
choice of frailty tool.  
 
 
 
 
54 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
55 
 
Conclusion 
 Cancer patients have a decrease in physiological reserve, making frailty 
an important factor to determine the increased risk of adverse outcomes.  
The results of our systematic review and meta-analysis suggest that: 
1)  Frail cancer patients submitted to surgery are at higher risk of unplanned 
readmission; 
2) This association is also made for readmission with a longer follow-up 
period and cancer type.  
3) No association was found for frailty and risk of readmission with severity 
of frailty, 30 day follow-up period and type of treatment. 
The results of our cross-sectional study suggest that: 
1) Frailty prevalence ranges widely according to the frailty instrument within 
the same population;  
2)  There was a poor agreement between the different frailty tools, indicating 
that different methods select different patients as frail, highlighting that 
care should me made when taking decisions based on a specific 
instrument.  
Further studies need to be done to define a gold standard tool, which will probably 
be case and context-specific.  
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